EntryPoint Capital’s Oruka Therapeutics ORKA Stock Holding History

EntryPoint Capital’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-6,120	Closed	-$300K	–	996
2026 Q1	$300K	Buy	+6,120	New	+$213K	0.09%	468

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EntryPoint Capital's ORKA Position: Q2 2026 in Review

EntryPoint Capital sold out of Oruka Therapeutics (ORKA) in Q2 2026, closing a stake of 6,120 shares — an estimated $300K sold.

EntryPoint Capital first reported a position in ORKA in Q1 2026 and held it in 1 quarter. The position peaked at $300K in Q1 2026. 255 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

EntryPoint Capital reported no remaining Oruka Therapeutics position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 6,120 Oruka Therapeutics shares in Q2 2026, an estimated $300K.
EntryPoint Capital first reported a position in Oruka Therapeutics in Q1 2026 and held it in 1 quarter.
EntryPoint Capital's Oruka Therapeutics position peaked at $300K in Q1 2026.
255 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.